Rx Pricing: Insulin Costs Would Go Up Under Senate Bill; Biden Pushes Summer Action On Broader Plan
CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.
You may also be interested in...
Private sector efforts to lower cost sharing for insulin continue but patient advocates and lawmakers still believe legislation is needed to tackle the issue in a comprehensive way.
Patient advocates are optimistic that ‘historic bill’ establishing price negotiation, inflation rebates and a spending cap in Medicare will pass into law.
The US pharmaceutical industry is finally on the right side of the inflation debate, with drug price increases clearly lagging well behind overall consumer price growth. It is, however, probably too late to make a difference in the prospects of price control legislation.